<DOC>
	<DOC>NCT00150618</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.</brief_summary>
	<brief_title>Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects with a primary diagnosis of ADHD Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test Male or nonpregnant female subject who agrees to comply with any applicable contraceptive requirements Subject has a current, uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as severe comorbid Axis II disorders or severe Axis I disorders Subject weighs less than 55 lbs or is morbidly overweight with a BMI =&gt; 35 Subject has a history of seizure during the last 2 years or a serious tic disorder, including Tourette's Disorder Subject is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>